| Authors: |
Little JS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Medina Pena A; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Kim EB; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Yee AJ; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Nadeem O; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Midha S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Raje N; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Frigault MJ; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Cirstea DD; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Hammond SP; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.; Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA. |
